MRKMerck Sharp & Dohme LLCRunning, no new patients
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Non-Small Cell Lung Cancer · Renal Cell Carcinoma · Melanoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 147 (final count)
- Started
- Dec 26, 2023
- Main results expected
- Apr 9, 2025
- Fully finished
- Feb 15, 2027
- Results posted
- Apr 8, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Who Prefer Pembrolizumab Plus Berahyaluronidase Alfa Subcutaneous (SC) As Assessed By Patient Preference Questionnaire (PPQ) Question 1
Measured over: Day 106
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06099782 · record last updated 2026-04-08 · checked 2026-11-09 15:47 UTC